SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

BERYL DRUGS

BSE: 524606 28 Jun 2025
Healthcare
₹ 18.82
Beryl Drugs Ltd. specializes in Pharmaceuticals within the Healthcare sector.

BERYL DRUGS - Share Price & Details

Market Cap
₹9.54
High /Low
46.0 / 17.4
Stock P/E
16.4
Book Value
₹18.7
Dividend Yield
0.0
ROCE
10.1
ROE
₹6.3
Face Value
10.0
PEG Ratio
0.26
EVEBITDA
₹4.85
Debt
4.08
CMP / FCF
17.2
Debt to equity
₹0.43
NP Ann
0.58
High price all time
53.0
Piotroski score
₹7.0
Graham Number
22.0
No. Eq. Shares
0.51
Net CF
₹0.69
Net profit
0.58
Price to book value
1.0
Interest Coverage
₹2.62
Low price all time
0.72
Industry PE
32.0
Reserves
₹4.41
Free Cash Flow
₹0.45

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
LOOKS HEALTH SERVICES LIMITEDNANANANA5.11256.0
Triochem Products Ltd.,NANANANA0
BERYL DRUGS LTD.NANANANA9.5416.4
Satiate Agri LimitedNANANANA8.55
DR LALCHANDANI LABS LIMITEDNANANANA7.7718.5

Peer Comparison Chart


About BERYL DRUGS

Beryl Drugs Ltd., with Security Code 524606, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Beryl Drugs Ltd Experiences Significant Buying Activity Amid Market Reversal Trends

(12 Jun 2025)
Beryl Drugs Ltd is experiencing notable buying activity, marking a reversal after four days of decline. The stock has gained 14.99% over the past month,...
Read more →

Beryl Drugs Faces Challenges Amid Shift to Mildly Bearish Outlook and Volatility

(11 Jun 2025)
Beryl Drugs has recently adjusted its evaluation score, reflecting a change in technical trends. The company has faced significant challenges over the past...
Read more →

Is Beryl Drugs overvalued or undervalued?

(11 Jun 2025)
As of June 2, 2025, Beryl Drugs is considered very attractive with a PE ratio of 9.89, an EV/EBITDA ratio of 4.98, and a price-to-book value of 1.04,...
Read more →

How has been the historical performance of the Beryl Drugs?

(07 Jun 2025)
Beryl Drugs has experienced fluctuating financial performance, with net sales declining from Rs 26.89 crore in Mar'23 to Rs 21.15 crore in Mar'25,...
Read more →

Who are in the management team of Beryl Drugs?

(07 Jun 2025)
As of March 2023, the management team of Beryl Drugs includes Sanjay Sethi (Managing Director), Sudhir Sethi (Chairman), Abhinav Naik, and Shreya Saraf...
Read more →

Beryl Drugs Adjusts Valuation Grade Amid Competitive Industry Landscape and Financial Metrics

(04 Jun 2025)
Beryl Drugs, a microcap in the Pharmaceuticals and Biotechnology sector, has adjusted its valuation, showcasing a P/E ratio of 9.38 and an EV to EBITDA...
Read more →